search
Back to results

Modulation of Steroid Immunosuppression by Alveolar Efferocytosis

Primary Purpose

Pulmonary Disease, Chronic Obstructive, Pneumonia, Bacterial

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Bronchoscopy with bilateral bronchoalveolar lavages
Sponsored by
VA Ann Arbor Healthcare System
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Pulmonary Disease, Chronic Obstructive focused on measuring Apoptosis, Bronchoscopy, Human, Mice, inbred strains, Macrophages, Alveolar, MicroRNAs, Streptococcus pneumoniae, Fluticasone

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Inclusion Criteria for healthy subjects without COPD:
  • Age 18-80 years, inclusive
  • Males or females
  • Never smoker (< 100 cigarettes in lifetime)

    • OR
  • Current smoker (>10 pack-years) with normal spirometry
  • Able to perform satisfactory spirometry
  • Abe to give informed consent
  • Able to complete questionnaires
  • Inclusion Criteria for COPD subjects:
  • Age 18-80 years, inclusive
  • Males or females
  • Current smoker

    • (>10 pack-years) & (≥1/2 pack/day)

      • OR
  • Former smoker

    • (>10 pack-years) & (>6 months of non-smoking)
  • Diagnosis of COPD by ATS/ERS1 criteria
  • Able to perform satisfactory spirometry
  • Able to give informed consent
  • Able to complete questionnaires
  • 1 ATS/ERS, American Thoracic Society/European Respiratory Society.

Exclusion Criteria:

  • Exclusion Criteria for healthy subjects without COPD:
  • Unstable cardiovascular disease, including uncontrolled hypertension, CHF, angina
  • Significant renal (creatinine >2.5) or hepatic dysfunction (Childs B or C)
  • Mental incompetence/active psychiatric illness
  • Prednisone or other immunosuppressive medications
  • Participation in another interventional experimental protocol within 6 weeks
  • Pregnancy
  • Use of antibiotics for any reason within 42 days
  • Judged to be unsuitable for bronchoscopy by PI
  • Resting SaO2<93%
  • FEV1 < 70% predicted
  • Respiratory infections within 42 days regardless of antibiotic use
  • Diagnosed COPD or Asthma
  • Use of inhaled corticosteroids
  • Active pulmonary tuberculosis or other serious chronic respiratory infection
  • Diffuse panbronchiolitis or Cystic fibrosis
  • Clinically significant bronchiectasis
  • History of thoracic radiation therapy for any cause
  • Other inflammatory or fibrotic lung disease
  • Exclusion Criteria for COPD subjects:
  • Unstable cardiovascular disease, including uncontrolled hypertension, CHF, angina
  • Significant renal (creatinine >2.5) or hepatic dysfunction (Childs B or C)
  • Mental incompetence/active psychiatric illness
  • Prednisone or other immunosuppressive medications
  • Participation in another interventional experimental protocol within 6 weeks
  • Pregnancy
  • Use of antibiotics for any reason within 42 days
  • Judged to be unsuitable for bronchoscopy by PI
  • Resting daytime SaO2<90% while breathing room air
  • FEV1 < 50% predicted
  • Respiratory infections within 42 days regardless of antibiotic use
  • Use of inhaled corticosteroids
  • Active pulmonary tuberculosis or other serious chronic respiratory infection
  • Diffuse panbronchiolitis or Cystic fibrosis
  • Clinically significant bronchiectasis
  • History of thoracic radiation therapy for any cause
  • Other inflammatory or fibrotic lung disease

Sites / Locations

  • VA Ann Arbor Healthcare System

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Healthy Participants

COPD participants

Arm Description

Procedure/Surgery: Bronchoscopy with bilateral bronchoalveolar lavages. Drugs: No test substances, only moderate conscious sedation using standard medications. Devices: No test devices.

Procedure/Surgery: Bronchoscopy with bilateral bronchoalveolar lavages. Drugs: No test substances, only moderate conscious sedation using standard medications. Devices: No test devices.

Outcomes

Primary Outcome Measures

Bactericidal activity of human alveolar macrophage against S. pneumoniae in vitro
Alveolar macrophages from volunteers will be be assayed for their ability to kill pneumococci in vitro following treatment with glucocorticoids, apoptotic cells or both. Participation of the subjects ends after bronchoscopy, and no clinical outcomes will be measured.

Secondary Outcome Measures

Mechanisms of human alveolar macrophage killing of S. pneumoniae in vitro
These same macrophages will also be assayed for production of mRNA and regulatory microRNAs (by RNA sequencing and quantitative real-time PCR and for cytokine and chemokine production.

Full Information

First Posted
January 23, 2017
Last Updated
April 26, 2022
Sponsor
VA Ann Arbor Healthcare System
Collaborators
University of Michigan
search

1. Study Identification

Unique Protocol Identification Number
NCT03034642
Brief Title
Modulation of Steroid Immunosuppression by Alveolar Efferocytosis
Official Title
Modulation of Steroid Immunosuppression by Alveolar Efferocytosis
Study Type
Interventional

2. Study Status

Record Verification Date
April 2022
Overall Recruitment Status
Completed
Study Start Date
October 1, 2015 (Actual)
Primary Completion Date
March 20, 2020 (Actual)
Study Completion Date
December 30, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
VA Ann Arbor Healthcare System
Collaborators
University of Michigan

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The long-term goals of this study are (a) to understand the biological underpinnings for the increased incidence of community-acquired pneumonia in patients with chronic obstructive pulmonary disease (COPD) who are treated with inhaled corticosteroids; and (b) to develop novel therapies to treated this problem using over-expression of micro-RNAs (miRNAs).
Detailed Description
Treating chronic obstructive pulmonary disease (COPD) patients with inhaled glucocorticosteroids has been convincingly shown to increase their risk of pneumonia, but the responsible mechanisms are undefined. Work from this laboratory suggests a possible mechanism, related to the increased numbers of cells dying by apoptosis in the lungs in COPD, especially in emphysema. Uptake of apoptotic cells ("efferocytosis") suppresses the ability of alveolar macrophages (AM) to fight infections. By markedly increasing AM efferocytosis, glucocorticoids plus apoptotic cells cause greater immune defects than either stimulus alone. These defects include reductions in killing of Streptococcus pneumoniae by human AM and murine AM in vitro, and in clearance of viable pneumococci from lungs of mice. This effect is called glucocorticoid augmented efferocytosis (GCAE). MicroRNAs (miRNAs) are 19-25 nucleotide-long non-coding RNAs that coordinately target large numbers of genes and reduce their protein products. Preliminary data imply that defective AM function is caused by down-regulation of specific miRNAs by GCAE (but not by apoptotic cells alone or glucocorticosteroids alone). The long-term goal of this project is to develop novel inhalational treatments based on transient over-expression of these specifically decreased miRNAs, to reverse defective AM immune function when COPD patients taking inhaled glucocorticoids present with community-acquired pneumonia. This project will use both ex vivo investigation of AM from human volunteers (never-smokers; smokers with normal spirometry; and COPD subjects who are current or former smokers), and an established murine model of pneumococcal pneumonia. Its immediate goals are to: (a) confirm that GCAE increases pneumococcal pneumonia risk and severity, and in the process, validate a murine model for testing strategies to reverse those defects; (b) define GCAE-induced AM defects functionally and by whole-transcriptome analysis, identifying genes and miRNAs uniquely regulated by the GCAE x pneumococcus interaction; (c) validate and optimize miRNA-over-expression to reverse the adverse effects of GCAE on AM defensive functions. Successful completion of this project could lead to more precisely personalized therapies and better outcomes in COPD, currently the third leading cause of death in the USA

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pulmonary Disease, Chronic Obstructive, Pneumonia, Bacterial
Keywords
Apoptosis, Bronchoscopy, Human, Mice, inbred strains, Macrophages, Alveolar, MicroRNAs, Streptococcus pneumoniae, Fluticasone

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
This study will analyze both healthy subjects (never-smokers and current- or ex-smokers) in one arm, and also subjects with COPD (current- or ex-smokers).
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Healthy Participants
Arm Type
Experimental
Arm Description
Procedure/Surgery: Bronchoscopy with bilateral bronchoalveolar lavages. Drugs: No test substances, only moderate conscious sedation using standard medications. Devices: No test devices.
Arm Title
COPD participants
Arm Type
Experimental
Arm Description
Procedure/Surgery: Bronchoscopy with bilateral bronchoalveolar lavages. Drugs: No test substances, only moderate conscious sedation using standard medications. Devices: No test devices.
Intervention Type
Procedure
Intervention Name(s)
Bronchoscopy with bilateral bronchoalveolar lavages
Intervention Description
Bronchoscopy with bilateral bronchoalveolar lavages
Primary Outcome Measure Information:
Title
Bactericidal activity of human alveolar macrophage against S. pneumoniae in vitro
Description
Alveolar macrophages from volunteers will be be assayed for their ability to kill pneumococci in vitro following treatment with glucocorticoids, apoptotic cells or both. Participation of the subjects ends after bronchoscopy, and no clinical outcomes will be measured.
Time Frame
24 hours
Secondary Outcome Measure Information:
Title
Mechanisms of human alveolar macrophage killing of S. pneumoniae in vitro
Description
These same macrophages will also be assayed for production of mRNA and regulatory microRNAs (by RNA sequencing and quantitative real-time PCR and for cytokine and chemokine production.
Time Frame
24 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Inclusion Criteria for healthy subjects without COPD: Age 18-80 years, inclusive Males or females Never smoker (< 100 cigarettes in lifetime) OR Current smoker (>10 pack-years) with normal spirometry Able to perform satisfactory spirometry Abe to give informed consent Able to complete questionnaires Inclusion Criteria for COPD subjects: Age 18-80 years, inclusive Males or females Current smoker (>10 pack-years) & (≥1/2 pack/day) OR Former smoker (>10 pack-years) & (>6 months of non-smoking) Diagnosis of COPD by ATS/ERS1 criteria Able to perform satisfactory spirometry Able to give informed consent Able to complete questionnaires 1 ATS/ERS, American Thoracic Society/European Respiratory Society. Exclusion Criteria: Exclusion Criteria for healthy subjects without COPD: Unstable cardiovascular disease, including uncontrolled hypertension, CHF, angina Significant renal (creatinine >2.5) or hepatic dysfunction (Childs B or C) Mental incompetence/active psychiatric illness Prednisone or other immunosuppressive medications Participation in another interventional experimental protocol within 6 weeks Pregnancy Use of antibiotics for any reason within 42 days Judged to be unsuitable for bronchoscopy by PI Resting SaO2<93% FEV1 < 70% predicted Respiratory infections within 42 days regardless of antibiotic use Diagnosed COPD or Asthma Use of inhaled corticosteroids Active pulmonary tuberculosis or other serious chronic respiratory infection Diffuse panbronchiolitis or Cystic fibrosis Clinically significant bronchiectasis History of thoracic radiation therapy for any cause Other inflammatory or fibrotic lung disease Exclusion Criteria for COPD subjects: Unstable cardiovascular disease, including uncontrolled hypertension, CHF, angina Significant renal (creatinine >2.5) or hepatic dysfunction (Childs B or C) Mental incompetence/active psychiatric illness Prednisone or other immunosuppressive medications Participation in another interventional experimental protocol within 6 weeks Pregnancy Use of antibiotics for any reason within 42 days Judged to be unsuitable for bronchoscopy by PI Resting daytime SaO2<90% while breathing room air FEV1 < 50% predicted Respiratory infections within 42 days regardless of antibiotic use Use of inhaled corticosteroids Active pulmonary tuberculosis or other serious chronic respiratory infection Diffuse panbronchiolitis or Cystic fibrosis Clinically significant bronchiectasis History of thoracic radiation therapy for any cause Other inflammatory or fibrotic lung disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jeffrey L. Curtis, M.D.
Organizational Affiliation
University of Michigan
Official's Role
Principal Investigator
Facility Information:
Facility Name
VA Ann Arbor Healthcare System
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48105
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
22615206
Citation
McCubbrey AL, Sonstein J, Ames TM, Freeman CM, Curtis JL. Glucocorticoids relieve collectin-driven suppression of apoptotic cell uptake in murine alveolar macrophages through downregulation of SIRPalpha. J Immunol. 2012 Jul 1;189(1):112-9. doi: 10.4049/jimmunol.1200984. Epub 2012 May 21.
Results Reference
background
PubMed Identifier
26243260
Citation
Freeman CM, Martinez CH, Todt JC, Martinez FJ, Han MK, Thompson DL, McCloskey L, Curtis JL. Acute exacerbations of chronic obstructive pulmonary disease are associated with decreased CD4+ & CD8+ T cells and increased growth & differentiation factor-15 (GDF-15) in peripheral blood. Respir Res. 2015 Aug 5;16(1):94. doi: 10.1186/s12931-015-0251-1.
Results Reference
background
PubMed Identifier
27161078
Citation
Adar SD, Huffnagle GB, Curtis JL. The respiratory microbiome: an underappreciated player in the human response to inhaled pollutants? Ann Epidemiol. 2016 May;26(5):355-9. doi: 10.1016/j.annepidem.2016.03.010. Epub 2016 Apr 7.
Results Reference
background
PubMed Identifier
27392936
Citation
Huang YJ, Erb-Downward JR, Dickson RP, Curtis JL, Huffnagle GB, Han MK. Understanding the role of the microbiome in chronic obstructive pulmonary disease: principles, challenges, and future directions. Transl Res. 2017 Jan;179:71-83. doi: 10.1016/j.trsl.2016.06.007. Epub 2016 Jun 23.
Results Reference
background
PubMed Identifier
27767327
Citation
Freeman CM, Curtis JL. Lung Dendritic Cells: Shaping Immune Responses throughout Chronic Obstructive Pulmonary Disease Progression. Am J Respir Cell Mol Biol. 2017 Feb;56(2):152-159. doi: 10.1165/rcmb.2016-0272TR.
Results Reference
background
PubMed Identifier
30633545
Citation
Verhamme FM, Freeman CM, Brusselle GG, Bracke KR, Curtis JL. GDF-15 in Pulmonary and Critical Care Medicine. Am J Respir Cell Mol Biol. 2019 Jun;60(6):621-628. doi: 10.1165/rcmb.2018-0379TR.
Results Reference
background
PubMed Identifier
32286855
Citation
Freeman CM, Curtis JL. It's Complicated: Lung Dendritic Cells in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2020 Aug 15;202(4):479-481. doi: 10.1164/rccm.202004-0899ED. No abstract available.
Results Reference
background
PubMed Identifier
32603192
Citation
Polverino F, Curtis JL. The ABCs of Granulomatous Lung Diseases: Age-associated B Cells. Am J Respir Crit Care Med. 2020 Oct 1;202(7):922-924. doi: 10.1164/rccm.202006-2261ED. No abstract available.
Results Reference
background
PubMed Identifier
31888755
Citation
He Y, Wang H, Zheng J, Beiting DP, Masci AM, Yu H, Liu K, Wu J, Curtis JL, Smith B, Alekseyenko AV, Obeid JS. OHMI: the ontology of host-microbiome interactions. J Biomed Semantics. 2019 Dec 30;10(1):25. doi: 10.1186/s13326-019-0217-1.
Results Reference
background
PubMed Identifier
31368812
Citation
Tighe RM, Redente EF, Yu YR, Herold S, Sperling AI, Curtis JL, Duggan R, Swaminathan S, Nakano H, Zacharias WJ, Janssen WJ, Freeman CM, Brinkman RR, Singer BD, Jakubzick CV, Misharin AV. Improving the Quality and Reproducibility of Flow Cytometry in the Lung. An Official American Thoracic Society Workshop Report. Am J Respir Cell Mol Biol. 2019 Aug;61(2):150-161. doi: 10.1165/rcmb.2019-0191ST.
Results Reference
background
PubMed Identifier
30352169
Citation
Curtis JL. B Cells Caught in the Act: Class Switching to IgA in Lung Lymphoid Follicles in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2019 Mar 1;199(5):548-550. doi: 10.1164/rccm.201810-1907ED. No abstract available.
Results Reference
background
PubMed Identifier
25987742
Citation
Stolberg VR, McCubbrey AL, Freeman CM, Brown JP, Crudgington SW, Taitano SH, Saxton BL, Mancuso P, Curtis JL. Glucocorticoid-Augmented Efferocytosis Inhibits Pulmonary Pneumococcal Clearance in Mice by Reducing Alveolar Macrophage Bactericidal Function. J Immunol. 2015 Jul 1;195(1):174-84. doi: 10.4049/jimmunol.1402217. Epub 2015 May 18.
Results Reference
result
PubMed Identifier
26718338
Citation
McCubbrey AL, Nelson JD, Stolberg VR, Blakely PK, McCloskey L, Janssen WJ, Freeman CM, Curtis JL. MicroRNA-34a Negatively Regulates Efferocytosis by Tissue Macrophages in Part via SIRT1. J Immunol. 2016 Feb 1;196(3):1366-75. doi: 10.4049/jimmunol.1401838. Epub 2015 Dec 30.
Results Reference
result
PubMed Identifier
25803243
Citation
Dickson RP, Erb-Downward JR, Freeman CM, McCloskey L, Beck JM, Huffnagle GB, Curtis JL. Spatial Variation in the Healthy Human Lung Microbiome and the Adapted Island Model of Lung Biogeography. Ann Am Thorac Soc. 2015 Jun;12(6):821-30. doi: 10.1513/AnnalsATS.201501-029OC.
Results Reference
result
PubMed Identifier
28196961
Citation
Dickson RP, Erb-Downward JR, Freeman CM, McCloskey L, Falkowski NR, Huffnagle GB, Curtis JL. Bacterial Topography of the Healthy Human Lower Respiratory Tract. mBio. 2017 Feb 14;8(1):e02287-16. doi: 10.1128/mBio.02287-16.
Results Reference
result
PubMed Identifier
26177175
Citation
Dickson RP, Erb-Downward JR, Prescott HC, Martinez FJ, Curtis JL, Lama VN, Huffnagle GB. Intraalveolar Catecholamines and the Human Lung Microbiome. Am J Respir Crit Care Med. 2015 Jul 15;192(2):257-9. doi: 10.1164/rccm.201502-0326LE. No abstract available.
Results Reference
result
PubMed Identifier
29565180
Citation
Mancuso P, Curtis JL, Freeman CM, Peters-Golden M, Weinberg JB, Myers MG Jr. Ablation of the leptin receptor in myeloid cells impairs pulmonary clearance of Streptococcus pneumoniae and alveolar macrophage bactericidal function. Am J Physiol Lung Cell Mol Physiol. 2018 Jul 1;315(1):L78-L86. doi: 10.1152/ajplung.00447.2017. Epub 2018 Mar 22.
Results Reference
result
PubMed Identifier
29676596
Citation
Finch DK, Stolberg VR, Ferguson J, Alikaj H, Kady MR, Richmond BW, Polosukhin VV, Blackwell TS, McCloskey L, Curtis JL, Freeman CM. Lung Dendritic Cells Drive Natural Killer Cytotoxicity in Chronic Obstructive Pulmonary Disease via IL-15Ralpha. Am J Respir Crit Care Med. 2018 Nov 1;198(9):1140-1150. doi: 10.1164/rccm.201712-2513OC.
Results Reference
result
PubMed Identifier
32518181
Citation
Erb-Downward JR, Falkowski NR, D'Souza JC, McCloskey LM, McDonald RA, Brown CA, Shedden K, Dickson RP, Freeman CM, Stringer KA, Foxman B, Huffnagle GB, Curtis JL, Adar SD. Critical Relevance of Stochastic Effects on Low-Bacterial-Biomass 16S rRNA Gene Analysis. mBio. 2020 Jun 9;11(3):e00258-20. doi: 10.1128/mBio.00258-20.
Results Reference
result
PubMed Identifier
32343599
Citation
Yue M, Kim JH, Evans CR, Kachman M, Erb-Downward JR, D'Souza J, Foxman B, Adar SD, Curtis JL, Stringer KA. Measurement of Short-Chain Fatty Acids in Respiratory Samples: Keep Your Assay above the Water Line. Am J Respir Crit Care Med. 2020 Aug 15;202(4):610-612. doi: 10.1164/rccm.201909-1840LE. No abstract available.
Results Reference
result

Learn more about this trial

Modulation of Steroid Immunosuppression by Alveolar Efferocytosis

We'll reach out to this number within 24 hrs